For Healthcare professionals

DigiStain – the UK’s First Breast Cancer Risk Profiling Technology

Digistain for Healthcare professionals provides easy-to-read reporting and clear actionable information to help determine the best course of treatment and indeed whether cytotoxic therapy in addition to hormone therapy is required.

Digsitain demonstrated equivalence to the leading NICE approved Next-Generation-Sequencing (NGS) tumour profiling tests. In a double-blinded study with over 840 hormone-positive early stage breast cancer patients.

It is based on a mature, sensible approach using well-established analytical technology for chemical analysis that until today has not been used for cancer patient risk scoring.

0 %

Reduction in patient waiting times

0 %

Equivalent to the best in class risk profiling tests used today

0 %

Overall cost reduction through avoided chemotherapy

0 %

Multi-site reproducibility with routinely trained lab technicians

Digistain’s has undergone several clinical trials demonstrating a prognostic score with risk classification equivalent to the best in class genomic tests

The product of 15 years of R&D pioneered by respected cancer researchers from Imperial College London and Cancer Research UK

Digistain's Prognostic Score uses a proprietary optical scan of the tumour tocapture a spectral signature (of over 10,000 data points) that is unique to every patient.

Clinical Evidence: Equivalent To Gold Standard NGS Solutions

Mammaprint

5 years: 0.22

10 years 0.29

Prosigna

5 years: 0.16

10 years 0.24

Digistain

5 years: 0.23

10 years 0.35

In a double-blinded study with over 840 hormone-positive early stage breast cancer patients Digsitain demonstrated unequivocal equivalence to the leading NICE approved Next-Generation-Sequencing (NGS) tumour profiling tests

Digistain in Action

“Typical prognostic factors such as the NPI (the gold standard used across the world) have a hazard ratio of around 2. A hazard ratio >4 is excellent. Digistain appears to be a much better classifier of risk than other biomarkers I’ve seen used in clinics today”

Prof Andrew Green Ian Ellis’s Group Nottingham University